About this trial

A registry for the study of the epidemiology, clinical course, and progression of myelodysplastic neoplasms (MDS), myelodysplastic/myeloproliferative neoplasms (MDS/MPN overlap syndromes), and their precursor syndromes (CHIP, CCUS)

Eligibility criteria

Qualifiers

Diagnosis of myelodysplastic syndrome (MDS), MDS/MPN overlap syndrome or evidence of myelodysplastic precursor syndrome, defined as clonal haematopoiesis without cytopenia (clonal haematopoiesis of indeterminate potential, CHIP) or clonal haematopoiesis with cytopenia (clonal cytopenia of undetermined significance, CCUS) in accordance with current WHO criteria

Age ≥18 years

Submission of a signed consent form for participation in the MDS Registry

Disqualifiers

No exclusion criteria have been established with regard to the registry's primary objective. In particular, patients with comorbidities and those receiving non-curative treatment may be explicitly included in order to provide a realistic picture of actual care practices

Inclusion in the registry is excluded in cases where a written consent form is not available or where patients are unable to understand the nature and implications of participating in this registry

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

No trial groups listed

Locations

1
Universitätsklinikum Carl Gustav Carus Dresden01307, Dresden Germany

Sponsors and collaborators

Technische Universität Dresden

Lead sponsor